HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Follow-Up Questions
HLVX の株価パフォーマンスは？
HLVX の現在の価格は $2.09 で、最終取引日から 0% decreased 変動しました。
Hillevax Inc の主な事業テーマや業界は？
Hillevax Inc は Biotechnology 業界、セクターは Health Care に属しています。
